Korean J Pediatr.  2010 Nov;53(11):936-941. 10.3345/kjp.2010.53.11.936.

Treatment of juvenile rheumatoid arthritis

• Kim KN

• KMID: 2280906
• DOI: http://doi.org/10.3345/kjp.2010.53.11.936

Abstract

The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.

Keyword

Juvenile arthritis; Child; Therapy; Non-steroidal anti-inflammatory agents; Disease modifying antirheumatic drugs

MeSH Terms

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antirheumatic Agents
Arthritis
Arthritis, Juvenile Rheumatoid
Child
Humans
Immunoglobulin G
Inflammation
Receptors, Tumor Necrosis Factor
Infliximab
Etanercept
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor